Smaller sized doses for perioral treatment than for higher facial purposes are utilised because the oral musculature responds much more strongly to exactly the same BTX-A dosing. Only one planning of botulinum toxin type B (MyoBloc®/NeuroBloc®) exists. Its sole sign and FDA approval lies in treatments of cervical dystonia. https://hugog825tbi7.wikirecognition.com/user